Appetite News and Research

RSS

Digital companion apps help secure long-term habits during GLP-1 therapy

Glucagon-like peptide-1 (GLP-1) medications have revolutionized weight management, yet high dropout rates and rapid weight regain remain significant hurdles for many patients.

9 Sep 2026

Non-nutritive sweeteners may aid sugar reduction without affecting weight or health

The review, led by Eva Marija Čad of the University of Ljubljana and Wageningen University & Research, alongside Professor Graham Finlayson of the University of Leeds and colleagues from other institutions in the Netherlands, Denmark, Spain and Belgium, was developed in connection with a 2025 webinar series hosted by the Institute for the Advancement of Food and Nutrition Sciences (IAFNS).

9 Sep 2026

Stevia tastes sweet, but does your body react as if sugar is coming?

In a randomized, double-blind crossover study, researchers tested stevia alone and with glucose in adults with normal weight, overweight, or type 2 diabetes to assess acute effects on blood glucose, insulin, gut hormones, appetite, and subsequent food intake. Stevia produced no significant changes in the measured glycemic or hormonal responses compared with water and did not significantly modify responses to glucose, while appetite and subsequent energy intake were also generally unchanged.

8 Sep 2026

Dual-drug microneedle patch targets inflammation and fat browning

The worldwide obesity crisis has become a dominant public health crisis across the globe. Over 3 billion people worldwide currently suffer from obesity, and forecasts warn the number will rise above 4 billion by 2035, accounting for more than half the global population.

4 Sep 2026

Childhood obesity prescriptions for GLP-1 drugs surge in the U.S.

Although the number of US children under age 12 with obesity being prescribed the weight loss drugs Saxenda, Wegovy, and Zepbound remains low, the number is 310 times higher in June 2026 than it was in 2019, when the drugs were initially prescribed, a new study shows.

4 Sep 2026

The obesity-microbiome story is more complicated than ‘good’ and ‘bad’ bacteria

This review finds that obesity is linked to reciprocal interactions between diet, the gut microbiome, microbial metabolites, and host metabolic pathways that influence appetite, insulin sensitivity, inflammation, and energy balance across the lifespan. It highlights diet as a particularly tractable way to influence this system, while emphasizing that microbiome changes associated with GLP-1 therapies remain difficult to separate from weight loss and that functional multi-omics approaches may help enable more personalized interventions.

3 Sep 2026

Study links popular weight-loss drugs to increased male hair loss

Men already at risk genetically for the most common form of hair loss have a 7 percent added risk of losing their hair if they use drugs like Ozempic, Wegovy, and Zepbound for type 2 diabetes and obesity, a new study shows.

3 Sep 2026

Why addiction researchers are paying closer attention to GLP-1 drugs

A Journal of Clinical Investigation Viewpoint highlights growing evidence that GLP-1 receptor agonists, particularly semaglutide, may reduce alcohol consumption and some other substance-related outcomes by acting on brain systems involved in reward, motivation, stress, and emotion. However, the authors caution that efficacy for substance use disorders is not yet firmly established and call for further research into optimal dosing, treatment duration, patient selection, mechanisms, and effects across different addictions.

2 Sep 2026

Researchers identify a previously unknown mechanism that can drive cancer cachexia

Researchers at Helmholtz Munich, the Heidelberg Faculty of Medicine at Heidelberg University, the German Center for Diabetes Research (DZD) and the Technical University of Munich (TUM), have identified a previously unknown mechanism that can drive cancer cachexia – a wasting process in the body that primarily affects muscle and fat tissue.

1 Sep 2026

Breastmilk from cannabis users showed differences, but cannabis may not be the whole story

A narrative review found that maternal cannabis use may be associated with differences in breastmilk fat, protein, lactose, and the immune factor secretory immunoglobulin A, but evidence comes primarily from only two human studies and remains limited and inconsistent. The authors stress that maternal diet, food security, socioeconomic circumstances, and other forms of adversity could confound these associations and should be incorporated into future research.

31 Aug 2026

Experts call for safer weight loss as concerns grow over GLP-1 use

An editorial in Diabetology International argues that inappropriate GLP-1 use should be judged not only by regulatory compliance or off-label prescribing, but also by whether weight reduction is medically safe, nutritionally adequate, and properly supervised. Drawing on Japanese reports of ketosis and ketoacidosis following inappropriate tirzepatide use, the authors call for greater attention to the risks of unsafe weight-loss practices alongside medication-related harms.

30 Aug 2026

Rapid rise of GLP-1 medicines brings obesity and eating disorders together

Obesity and eating disorders have traditionally been treated as separate areas of healthcare – but the rapid rise of GLP-1 medicines is increasingly bringing the two together.

28 Aug 2026

Personalized nutrition promotes weight loss without counting calories

The great majority of people taking part in a study lost weight by following personalised nutritional insights, rather than going on a calorie counting or restrictive diet, reveal findings from a new study.

27 Aug 2026

Can caffeine make you mentally sharper in the morning? This study tested the idea

In a controlled crossover study of 51 recreationally active young men with low habitual caffeine intake, researchers tested whether 300 mg of caffeine taken about an hour before morning testing affected cognition, mood, temperature, appetite, and related outcomes, with reactive agility assessed in 27 participants. Caffeine did not improve cognitive or reactive agility performance or meaningfully alter mood, tiredness, appetite, or thermoregulation under the study conditions.

27 Aug 2026

Molecular switch ERBB4 linked to broad range of Alzheimer's pathologies

What if amyloid plaques are not the whole story of Alzheimer's disease? New research suggests that a broad range of Alzheimer's pathologies may be orchestrated by a molecular switch called ERBB4 when it turns on in the wrong neurons.

26 Aug 2026

GLP-1 meds prompt rethink of obesity and eating disorder care

Obesity and eating disorders have traditionally been treated as separate areas of healthcare – but the rapid rise of GLP-1 medicines is increasingly bringing the two together.

26 Aug 2026

GLP-1 drugs may reshape obesity care, but clinicians still have questions

Interviews with 11 healthcare professionals in a UK specialist weight management service found generally positive attitudes toward injectable GLP-1 drugs, alongside limited formal training and uncertainty about how the medications should be integrated with behavioral care. Participants anticipated potential benefits for confidence and weight management but also raised concerns about treatment discontinuation, behavioral engagement, and evolving professional responsibilities.

26 Aug 2026

UC Berkeley researchers find new potential treatment for obesity and diabetes

Over the past five years, medications called GLP-1s have revolutionized the treatment of metabolic disorders like obesity, diabetes and fatty liver diseases.

21 Aug 2026

Semaglutide trial targets people with liver disease, obesity and alcohol addiction

A new study -- co-led by the University of Plymouth, University Hospitals Plymouth NHS Trust, and the NIHR Biomedical Research Centre: Nottingham -- is being launched into a treatment for people impacted by liver disease, obesity and alcohol addiction.

19 Aug 2026

Weight-loss drug users turn to social media over doctors for advice, Coventry University study finds

Researchers from the UK and Canada found that users of GLP-1 medications - weight-loss drugs such as Ozempic, Wegovy and Mounjaro that help regulate appetite and blood sugar levels - often rely on social media, online forums, friends and family for information about the drugs.

19 Aug 2026